On September 2, 2026 Mabqi reported the participation of Anne Chevrel, Johanna Marines and Cécile Durand in the Festival of Biologics 2026, taking place from October 13 to 15 in Basel, Switzerland—Europe’s largest biologics event.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Our company will showcase its latest advances with a strong presence at this year’s congress.
Not 1 but 2 oral presentations!
– Next-Generation Tumor-Specific Anti-CD30 ADC as a New Therapy in Hemato-Oncology – Anne Chevrel, Head of Discovery – Wednesday, October 14 at 12.10.
– A Novel Pan-Cancer TRPV6-Targeted Therapy Driving Antitumor Activity Through Ion Channel Modulation– Johanna Marines, Head of Preclinical Development, Wednesday, October 14 at 12.30.
Two Poster presentations:
– MQI-201: A pan cancer immunotherapy targeting TRPV6 to convert cold tumors into hot tumors
– MQI-181: Tumor-specific anti-CD30 ADC limiting sink effect and demonstrating enhanced in vivo efficacy
Don’t miss the opportunity to meet our team at our booth in the Choose France Pavillon. Feel free to drop us a line or to schedule or contacts us through the networking app to schedule a meeting.
This major international gathering brings together over 3,000 experts from across the biologics and ATMP value chain, covering everything from early-stage discovery to commercialization. The event spans antibody therapies, cell and gene therapies, immunotherapies, and biosimilars.
We’re proud to be part of this vibrant community of scientists, innovators, and industry leaders shaping the future of large molecule therapeutics.
(Press release, Mabqi, SEP 2, 2026, View Source [SID1234670534])